Key result
Ezetimibe and niacin are reviewed for their research data and potential usefulness as additional lipid-lowering therapies to further reduce cardiovascular events in coronary heart disease.
Why the study?
Does adding ezetimibe or niacin to HMG-CoA reductase therapy reduce cardiovascular events in patients with or at risk of coronary heart disease?
Does adding ezetimibe or niacin to HMG-CoA reductase therapy reduce cardiovascular events in patients with or at risk of coronary heart disease?
This review examines the research data and potential usefulness of ezetimibe and niacin as add-on therapies to statins for reducing cardiovascular events.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open the need for outcome trials on ezetimibe and niacin as statin add-ons.
Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy. This paper will examine two of the more popular secondary agents, ezetimibe and niacin, and describe their research data and potential for usefulness in further reducing cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Robert Guthrie (2010) conducted a review in Coronary Heart Disease. Ezetimibe and Niacin was evaluated. Ezetimibe and niacin are reviewed for their research data and potential usefulness as additional lipid-lowering therapies to further reduce cardiovascular events in coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: